What is Tevogen?
Tevogen Bio operates at the intersection of immunology and artificial intelligence, specializing in the development of precision T-cell immunotherapies. By utilizing its proprietary ExacTcell technology platform, the company is pioneering a new class of off-the-shelf, personalized cell therapies designed to treat infectious diseases and various forms of cancer. Unlike traditional, resource-intensive immunotherapy models, Tevogen focuses on scalability and cost-effectiveness, aiming to democratize access to life-saving medical interventions. The integration of AI-driven research initiatives allows the firm to accelerate target identification, effectively shortening the drug development lifecycle and enhancing the precision of its clinical candidates.
How much funding has Tevogen raised?
Tevogen has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2024): $50M, investors not publicly disclosed
Key Investors in Tevogen
Undisclosed Investors
What's next for Tevogen?
With this major strategic investment, Tevogen is poised to transition its lead candidates through critical clinical milestones. The capital will likely be deployed to scale manufacturing capabilities and expand the reach of the ExacTcell platform, ensuring that the company remains at the forefront of the immunotherapy sector. As the firm moves deeper into its clinical-stage development, the focus will shift toward validating the efficacy of its off-the-shelf solutions in broader patient populations. By maintaining a lean, technology-first operational model, Tevogen is strategically positioned to disrupt the current immunotherapy landscape, potentially setting new benchmarks for both clinical outcomes and economic accessibility in the biotechnology industry.
See full Tevogen company page
